Radiotherapy for thymic tumors after surgery
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial
NA · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT06189183
This study tests if a special type of radiation therapy after surgery can help people with certain thymic tumors recover better and have fewer side effects.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06189183 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and side effects of adjuvant hypofractionation radiotherapy in patients with thymic epithelial tumors following complete surgical resection. It focuses on patients with stage II and III thymic carcinoma and stage III thymoma, assessing how this treatment can improve outcomes post-surgery. The study aims to determine the optimal approach to enhance recovery while minimizing toxicity.
Who should consider this trial
Good fit: Ideal candidates include individuals with histologically confirmed thymoma or thymic carcinoma who have undergone complete resection and meet specific health criteria.
Not a fit: Patients with uncontrolled comorbidities, prior thoracic radiotherapy, or those who are pregnant or nursing may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve survival rates and quality of life for patients with thymic tumors after surgery.
How similar studies have performed: While there have been studies on radiotherapy for thymic tumors, the specific approach of hypofractionation in this context is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Thymoma and Thymic carcinoma confirmed by histology or cytology * R0 resection (complete resection) * stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas. * Karnofsky performance status(KPS) 80, 90 or 100. * Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count\>1.5×109 /L, platelet count\>80×109 /L, hemoglobin ≥10g/dL. Exclusion Criteria: * Prior thoracic radiotherapy. * Uncontrolled Comorbidities. * Pregnant or nursing mother. * Pneumonia
Where this trial is running
Beijing, Beijing
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College — Beijing, Beijing, China (RECRUITING)
Study contacts
- Principal investigator: Tao Zhang, Dr. — National Cancer Center/Cancer Hospital, CAMS
- Study coordinator: Tao Zhang, Dr.
- Email: zhangt10@126.com
- Phone: 8618911006677
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thymus Neoplasms, Adjuvant Radiotherapy